Kyowa Kirin's bardoxolone program down but not quite out
This article was originally published in Scrip
Kyowa Hakko Kirin has decided to discontinue a Japanese Phase II clinical trial with bardoxolone methyl for use in chronic kidney disease patients with type 2 diabetes, but has not completely ruled out a new development program in the indication.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.